The issues related to haemostatic disorders and their treatment are being widely discussed in the literature concerning the diagnosis and management of patients diagnosed with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [1][2][3]. The findings of numerous worldwide studies have demonstrated that the haemostatic system is one of the most important systems substantially impaired by the viral infection, which can result in serious life-threatening complications [4][5][6]. It is already known that hypercoagulation [7,8] is the dominant coagulopathy in patients infected with SARS-CoV-2. Its consequences in the form of blood clots and emboli in the blood vessels of various organs in combination with thrombocytopathy lead to severe disorders of haemostasis in some patients and require ICU treatment [9][10][11]. According to the literature data, the incidence of thromboembolic incidents in this group of patients reaches 43% and increases with the length of hospitalization [12,13]. The incidence of pulmonary embolism, which is observed most frequently, is six-fold higher in patients

No abstract

No abstract

No abstract